AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39191095 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-week multidisciplinary inpatient rehabilitation
Number of subjects: 0
Study 39191132 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-skin sparing mastectomy (non-SSM)
Number of subjects: 153
Study 39191132 — intervention group
Group type: COMPARATOR
Intervention: Skin sparing mastectomy (SSM)
Number of subjects: 153
Study 39191270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Treatment Score post-5 years (CTS5)
Number of subjects: 1862
Study 39191270 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 1862
Study 39191270 — intervention group
Group type: EXPERIMENTAL
Intervention: N3 status
Number of subjects: 1862
Study 39191270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 1862
Study 39191270 — intervention group
Group type: EXPERIMENTAL
Intervention: CTS5 risk categories
Number of subjects: 1862
Study 39191373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional tele-rehabilitation programme
Number of subjects: 60
Study 39191568 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy
Number of subjects: 54
Study 39191745 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 booster (BB-B)
Number of subjects: 0
Study 39191745 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac booster (CC-C)
Number of subjects: 0
Study 39191745 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac (CC-C)
Number of subjects: 0
Study 39191745 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (CC-B)
Number of subjects: 0
Study 39191755 — intervention group
Group type: EXPERIMENTAL
Intervention: Vactosertib (200 mg twice daily) in combination with pomalidomide
Number of subjects: 0
Study 39191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation of an enlarging metastasis with continued ICI for a minimum of two additional cycles
Number of subjects: 17
Study 39191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 17
Study 39191809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled enriched heparin
Number of subjects: 27
Study 39191809 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 27
Study 39191926 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Social condition (remotely delivered lifestyle intervention)
Number of subjects: 329
Study 39191926 — intervention group
Group type: COMPARATOR
Intervention: Traditional condition (in-person delivered lifestyle intervention)
Number of subjects: 329
Study 39191926 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Social condition
Number of subjects: 329
Study 39191926 — intervention group
Group type: COMPARATOR
Intervention: Traditional condition
Number of subjects: 329
Study 39192022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Number of subjects: 32
Study 39192022 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 39192036 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation CAR T cells (HD-CAR-1) targeting CD19
Number of subjects: 9
Study 39192162 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg two times daily for 24 weeks
Number of subjects: 52
Study 39192162 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine 1 g t.i.d. for 24 weeks (Control)
Number of subjects: 52
Study 39192209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package (point-of-care tests including COVID-19 antigen tests, a diagnostic algorithm, and training and communication packages)
Number of subjects: 1098
Study 39192209 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1098
Study 39192209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 1098
Study 39192287 — intervention group
Group type: EXPERIMENTAL
Intervention: Predetected MDR Gram-negative bacteria
Number of subjects: 279
Study 39192287 — intervention group
Group type: EXPERIMENTAL
Intervention: V-V ECMO-acquired MDR Gram-negative bacteria
Number of subjects: 279
Study 39192287 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual hospital V-V ECMO volume
Number of subjects: 279
Study 39192287 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 279
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS diagnosed within the first 24 hours
Number of subjects: 439
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II bleeding
Number of subjects: 439
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term vasopressor use
Number of subjects: 439
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of acute coagulopathy
Number of subjects: 439
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of pneumonia
Number of subjects: 439
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 439
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 439
Study 39192291 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest classifier predictive ability
Number of subjects: 439
Study 39192309 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning (SDL) model training based on Knowles' SDL principles
Number of subjects: 72
Study 39192309 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning model (TLM)
Number of subjects: 72
Study 39192309 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed learning (SDL) model
Number of subjects: 72
Study 39192331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis Transition and Recovery (STAR) program
Number of subjects: 16
Study 39192339 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial plus RB-PDT
Number of subjects: 2
Study 39192339 — intervention group
Group type: COMPARATOR
Intervention: Topical antimicrobial plus sham RB-PDT
Number of subjects: 2
Study 39192345 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep It Up! (KIU!), an evidence-based eHealth HIV prevention program
Number of subjects: 85
Study 39192350 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 or 10 mg twice daily (BID)
Number of subjects: 8404
Study 39192350 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 11 mg once daily (considered as tofacitinib 5 mg BID)
Number of subjects: 8404
Study 39192350 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 3 and 3b/4 studies data
Number of subjects: 8404
Study 39192350 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAL Surveillance data
Number of subjects: 8404
Study 39192597 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated preoperative radiotherapy (RT) 15 × 2.85 Gy
Number of subjects: 120
Study 39193038 — intervention group
Group type: EXPERIMENTAL
Intervention: TARA intervention (12-week mindfulness-based training)
Number of subjects: 100
Study 39193038 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 100
Study 39193146 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) in the mesencephalic locomotor region (MLR)
Number of subjects: 62
Study 39193146 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 62
Study 39193146 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 62
Study 39193150 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 152
Study 39193150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 39193190 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab (VenR) for 2 years, with VenR for the first 6 months.
Number of subjects: 389
Study 39193190 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (BR) for 6 months.
Number of subjects: 389
Study 39193194 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-tracking apps (Strava, Pacer, MapMyWalk, and PokémonGo) used at least three times per week for 10 weeks
Number of subjects: 462
Study 39193194 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 462
Study 39193207 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed albuterol-budesonide 180/160 µg pressurized metered-dose inhaler (pMDI)
Number of subjects: 0
Study 39193207 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39193419 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab; specific dosage and duration not mentioned.
Number of subjects: 0
Study 39193463 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) in addition to conventional medication, 12 EA sessions over 6 weeks.
Number of subjects: 104
Study 39193463 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group receiving only conventional medication.
Number of subjects: 104
Study 39193596 — intervention group
Group type: COMPARATOR
Intervention: New radar device for diagnosing OSA
Number of subjects: 0
Study 39193655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mcg/kg dexmedetomidine
Number of subjects: 67
Study 39193655 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mcg/kg dexmedetomidine
Number of subjects: 67
Study 39193655 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mcg/kg dexmedetomidine
Number of subjects: 67
Study 39193655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 39193706 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 6 weeks (20h-fasting/4h-eating)
Number of subjects: 39
Study 39193706 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle
Number of subjects: 39
Study 39193709 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan
Number of subjects: 4822
Study 39193709 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4822
Study 39193773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 39193773 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39194012 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure-based cognitive behavior therapy (ECBT) for 12 weeks
Number of subjects: 309
Study 39194024 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting strategy (no antimicrobial administration for ventilator-associated tracheobronchitis, antimicrobials prescribed only for ventilator-associated pneumonia, sepsis, septic shock, or another infectious diagnosis)
Number of subjects: 0
Study 39194024 — intervention group
Group type: COMPARATOR
Intervention: Routine antimicrobial treatment strategy for seven days
Number of subjects: 0
Study 39194024 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting strategy
Number of subjects: 0
Study 39194097 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 50
Study 39194097 — intervention group
Group type: COMPARATOR
Intervention: Bilevel positive airway pressure
Number of subjects: 50
Study 39194206 — intervention group
Group type: EXPERIMENTAL
Intervention: iAST's first three antibiotic recommendations
Number of subjects: 325
Study 39194206 — intervention group
Group type: COMPARATOR
Intervention: Doctor's prescribed antibiotics
Number of subjects: 325
Study 39195506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligomalt (50 g)
Number of subjects: 15
Study 39195506 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (50 g)
Number of subjects: 15
Study 39196095 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 39196095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39196191 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39196551 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (fish oil) 2.4 g per day until 1 week post partum
Number of subjects: 736
Study 39196551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 736
Study 39196551 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (fish oil)
Number of subjects: 736
Study 39196580 — intervention group
Group type: EXPERIMENTAL
Intervention: Funnel-shaped intraperitoneal mesh
Number of subjects: 143
Study 39196580 — intervention group
Group type: COMPARATOR
Intervention: No mesh (control)
Number of subjects: 143
Study 39196631 — intervention group
Group type: EXPERIMENTAL
Intervention: School safety interventions in schools that have experienced a school shooting
Number of subjects: 12
Study 39196631 — intervention group
Group type: EXPERIMENTAL
Intervention: Schools that have experienced a school shooting
Number of subjects: 12
Study 39196631 — intervention group
Group type: COMPARATOR
Intervention: Schools that have never experienced a school shooting
Number of subjects: 12
Study 39196651 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0
Study 39196651 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study 39196693 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 605
Study 39196693 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 605
Study 39196713 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary revascularization (<24 h)
Number of subjects: 2343
Study 39196713 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative strategy
Number of subjects: 2343
Study 39196713 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes in elderly patients
Number of subjects: 2343
Study 39196713 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes in younger patients
Number of subjects: 2343
Study 39196855 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Educators (PCEs) integrated into existing hospital wards
Number of subjects: 24
Study 39196855 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Educators (PCEs)
Number of subjects: 24
Study 39197067 — intervention group
Group type: EXPERIMENTAL
Intervention: N-TEC implantation
Number of subjects: 5
Study 39197072 — intervention group
Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel (ide-cel)
Number of subjects: 0
Study 39197072 — intervention group
Group type: COMPARATOR
Intervention: standard regimens (SRs)
Number of subjects: 0
Study 39197113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 518
Study 39197113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 39197275 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based health education, home visits, and information flyers along with usual care
Number of subjects: 320
Study 39197275 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 39197510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensifentrine (3 mg tid for 24 weeks)
Number of subjects: 1549
Study 39197510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1549
Study 39197976 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4614
Study 39197976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 4614
Study 39197976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4614
Study 39197976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4614
Study 39198005 — intervention group
Group type: EXPERIMENTAL
Intervention: UK embryologists
Number of subjects: 740
Study 39198005 — intervention group
Group type: COMPARATOR
Intervention: US embryologists
Number of subjects: 740
Study 39198005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both UK and US embryologists
Number of subjects: 740
Study 39198005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 740
Study 39198011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based iodinated contrast media during HSG
Number of subjects: 69
Study 39198011 — intervention group
Group type: COMPARATOR
Intervention: Water-based iodinated contrast media during HSG
Number of subjects: 69
Study 39198799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg via HandiHaler
Number of subjects: 36
Study 39198799 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated COPD patients and healthy volunteers)
Number of subjects: 36
Study 39198824 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTS + AAR
Number of subjects: 1200
Study 39198824 — intervention group
Group type: COMPARATOR
Intervention: AAR alone
Number of subjects: 1200
Study 39198860 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 90
Study 39198860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 39198868 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 110
Study 39198875 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM-DB (upper limb elevations with simultaneous deep breathing)
Number of subjects: 22
Study 39198875 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM (upper limb elevations without deep breathing)
Number of subjects: 22
Study 39198875 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM-DB
Number of subjects: 22
Study 39198875 — intervention group
Group type: COMPARATOR
Intervention: ROM
Number of subjects: 22
Study 39198900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, interprofessional family support intervention (FSI)
Number of subjects: 896
Study 39198900 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 896
Study 39198915 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Model (community intervention delivered by volunteers)
Number of subjects: 79488
Study 39198915 — intervention group
Group type: COMPARATOR
Intervention: Facility Model (standard care with HAP)
Number of subjects: 79488
Study 39198915 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Model
Number of subjects: 79488
Study 39199367 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IL-10 levels
Number of subjects: 1002
Study 39199367 — intervention group
Group type: COMPARATOR
Intervention: IL-10 haplotypes
Number of subjects: 1002
Study 39199651 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning methods (random survival forests, survival neural networks)
Number of subjects: 0
Study 39199651 — intervention group
Group type: COMPARATOR
Intervention: Cox proportional hazard model
Number of subjects: 0
Study 39199651 — intervention group
Group type: COMPARATOR
Intervention: Extended Cox model with time-varying effects
Number of subjects: 0
Study 39199994 — intervention group
Group type: EXPERIMENTAL
Intervention: RHB-104 (triple antimicrobial therapy)
Number of subjects: 0
Study 39199994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39200725 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39201126 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMG biofeedback-assisted core strengthening exercises with kinesiotaping
Number of subjects: 24
Study 39201126 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strengthening exercises with kinesiotaping
Number of subjects: 24
Study 39201126 — intervention group
Group type: COMPARATOR
Intervention: Non-assisted exercises
Number of subjects: 24
Study 39201278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 0
Study 39201278 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39202082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy sessions of goal-directed and task-specific training (30 sessions, 3 per week for 10 weeks)
Number of subjects: 62
Study 39202082 — intervention group
Group type: COMPARATOR
Intervention: Usual Physical Therapy treatment
Number of subjects: 62
Study 39202235 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography-Angiography (OCT-A) assessment in CPA group
Number of subjects: 38
Study 39202235 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression of the optic chiasm in CPA patients
Number of subjects: 38
Study 39202235 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative parameters in CPA group
Number of subjects: 38
Study 39202581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC)
Number of subjects: 0
Study 39202581 — intervention group
Group type: COMPARATOR
Intervention: Continued Clomiphene Citrate (CC)
Number of subjects: 0
Study 39203915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Soybean (FSB) Supplementation (1 g once daily for 12 weeks)
Number of subjects: 110
Study 39204009 — intervention group
Group type: COMPARATOR
Intervention: AZD1222 (ChAdOx1 nCoV-19)
Number of subjects: 32450
Study 39206182 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual randomized physical activity-promoting intervention
Number of subjects: 0
Study 39206189 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine
Number of subjects: 0
Study 39206189 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine
Number of subjects: 0
Study 39206189 — intervention group
Group type: COMPARATOR
Intervention: AS04/Alum
Number of subjects: 0
Study 39206260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0
Study 39206260 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 39206307 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 β-casein infant formula with high sn-2 palmitate and casein phosphopeptides
Number of subjects: 0
Study 39206307 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39206389 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (GLP-1 agonist)
Number of subjects: 0
Study 39206494 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK retainer
Number of subjects: 46
Study 39206494 — intervention group
Group type: COMPARATOR
Intervention: Dead-soft coaxial fixed retainer (DSC)
Number of subjects: 46
Study 39206547 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic summary composite
Number of subjects: 763